|
||
Address correspondence to Stephen L. Nutt, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, 3050, Australia. Phone: 61-3-9345-2483; Fax: 61-3-9347-0852; email: nutt{at}wehi.edu.au
| Abstract |
|---|
|
|
|---|
Key Words: Prdm1 B-lymphopoiesis plasma cell antibody secretion terminal differentiation syndecan-1
| Introduction |
|---|
|
|
|---|
The B lymphocyteinduced maturation protein 1 (Blimp-1/Prdm1) has been proposed to have a preeminent role in regulating B cell terminal differentiation for the following reasons. Blimp-1 is expressed in ASCs from human and mouse, but not in memory cells (3). Notably, ectopic expression of Blimp-1 is sufficient to drive differentiation to a ASC phenotype (47). Antisense approaches (8) or a dominant-interfering Blimp-1 (9) are able to suppress exit from the cell cycle, a change essential for full ASC differentiation. In line with these studies, it has been recently demonstrated that mice lacking Blimp-1 in B cells produce greatly decreased levels of Ig and have a markedly reduced ASC compartment (10). Clearly, Blimp-1 expression is a key determinant in plasma cell development.
Blimp-1 is a transcriptional repressor that binds to DNA via conserved zinc finger motifs (11) and can interact with corepressors such as Groucho, histone deacetylases (12, 13), and the histone H3 methyltransferase, G9a (14). Blimp-1 repression is postulated to be essential for the extinction of c-myc expression and the exit from the cell cycle characteristic of terminal differentiation (15, 16). Blimp-1 directly represses the promoter of the Pax5 gene (17). Pax5 is required for the maintenance of B cell identity and represses the expression of XBP-1, itself an essential player in plasma cell development (18, 19). Many other putative Blimp-1 repressed genes have been identified using microarray technology; however, most have not been validated in the absence of Blimp-1 expression (20, 21). Collectively, these data support the notion of Blimp-1 expression being a master regulator of plasma cell differentiation.
The study of plasma cells is hampered by their heterogeneity in lifespan, surface phenotype, location, and the absence of virtually all B lineageassociated markers, making identification and isolation of ASCs a limiting step in their characterization (1, 2225). To overcome this difficulty, we have generated a mouse model where gfp has been introduced into the Blimp-1 locus. We show that Blimpgfp provides, for the first time, a definitive methodology to identify all plasma cells and reveals significant phenotypic heterogeneity in the ASC compartment. Moreover, the regulated expression of Blimpgfp defines the ontogeny of B cells from plasmablasts to long-lived plasma cells.
| Materials and Methods |
|---|
|
|
|---|
Genotyping.
Genomic DNA was digested with SpeI (3' arm) and hybridized to a 500-bp fragment of PCR-amplified genomic DNA 3' to the homology arms (see Fig. 1 A). C57BL/6 DNA gave a band of 5.8 kb, whereas correctly targeted clones gave an additional 4.5-kb band. PCR genotyping was performed using the primer combination: bl-1 5'-GGCAAGATCAAGTATGAGTGC-3', bl-2 5'-TGAGTAGTCACAGAGTACCCA-3', and bl-3 5'-GCGGAATTCATTTAATCACCCA-3'. PCR fragments of 611 and 531 bp were indicative of wild-type and targeted alleles, respectively.
Transplantation of Fetal Liver Cells.
Blimpgfp/+ (C57BL/6 Ly5.2) mice were intercrossed; fetal liver cells were isolated from E14.5 embryos and genotyped by PCR; and 13 x 106 fetal liver cells were injected into lethally irradiated C57BL/6 Rag1/ Ly5.1 congenic recipients (2 x 550 rad). Mice were analyzed after 8 wk. Successful reconstitution was analyzed using a Ly5.2-specific mAb.
Flow Cytometry.
The mAbs against CD19 (1D3), B220 (RA3-6B2), and Ly5.2 (ALI-4A2) were purified from hybridoma supernatants on protein GSepharose columns (Amersham Biosciences) and conjugated to biotin (Pierce Chemical Co.), allophycocyanin, phycoerythrin (ProZyme), and Alexa Fluor 633 (Molecular Probes) as recommended by the suppliers. Antisyndecan-1 (Synd-1; 281-2), MHCII (M5/114.15.2), CD43 (S7), CD62L (MEL-14), CD38 (90), CXCR4 (2B11), and CXCR5 (2G8) were obtained from BD Biosciences. Cells were analyzed on an LSR cytometer (BD Biosciences), and cell sorting was performed on high-speed flow cytometers (Moflo; DakoCytomation and BD Biosciences). In vivo cell proliferation was determined by bromodeoxyuridine (BrdU) incorporation. Mice were given an i.p. injection of 0.2 mg BrdU in PBS on day 1 and placed on BrdU drinking water (0.5 mg/ml in 2% glucose) for 4 d. GFP+ cell populations were sorted and fixed before being analyzed for BrdU uptake using an allophycocyanin-conjugated anti-BrdU mAb (BD Biosciences), following the protocol supplied by the manufacturer.
ELISA and ELISPOT Assay.
Ig levels were measured using ELISA as described previously (29). Antibodies were purchased from Southern Biotechnology Associates, Inc. and streptavidinhorseradish peroxidase or streptavidinAP conjugates were obtained from Sigma-Aldrich. ELISPOT assays were performed on MultiScreen-HA filter plates (Millipore). Cells were incubated for 4 h at 37°C on precoated 96-well filter plates and developed with AP substrate. Experiments were performed three times in triplicate.
In Vivo Induction of ASCs.
2 µg Escherichia coli LPS (Sigma-Aldrich) was injected intravenously into Blimpgfp/+ mice, and animals were analyzed daily for up to 7 d. Immunization was with a single i.p. injection of 100 µg 4(hydroxy-3)-nitrophenyl acetyl (NP) coupled to keyhole limpet hemocyanin (KLH) in the ratio of 13:1 (26). The antigen was precipitated onto alum and washed extensively before injection. Single cell suspensions from spleen and BM were analyzed as described previously (26). IgG1 ASC activity in 500 sorted GFP+ populations was determined using NP-specific ELISPOT (26).
In Vitro Cell Culture.
Naive B cells were purified from spleens by T cell complement depletion, Percoll gradient centrifugation, and B220 magnetic bead purification (Miltenyi Biotec) as described previously (29). Purified cells (95% IgM+IgD+B220+) were cultured at 105/ml with optimal concentrations of CD40L, 500 U/ml IL-4, and 2 ng/ml IL-5. 4 x 105 cells/ml were used for 20 µg/ml LPS stimulation. Cell membranes expressing mouse CD40L were prepared from Sf21 cells (42). Recombinant mouse IL-4 was obtained from R. Kastelein (DNAX Research Institute, Palo Alto, CA), and IL-5 was purchased from R&D Systems. Cell proliferation was assessed by pulsing cultures for 2 h with 1 µCi [methyl-3[H]thymidine (Amersham Biosciences). Cells were harvested onto glass-fiber mats, and incorporation was determined by scintillation counting.
Western Blotting.
An antiBlimp-1 mAb was generated in rats by immunization with a purified GSTBlimp-1 fusion protein consisting of the 141 amino acids lying between the PR and proline-rich domains of mouse Blimp-1 fused to the COOH terminus of glutathione-S-transferase in the vector pGEX-KT. mAbs were screened by Western blotting using B cell lines representing B cell and plasma cell stages. Reactivity with an endogenous protein of the appropriate size for Blimp-1 (
95 kD) protein was specifically detected for clone 6D3. Total protein extracts were produced from equivalent numbers of cells, and Western blotting was performed as described previously (43). Equal protein loading was confirmed using goat anti-ICSBP (C-19) and ß-actin (I-19) obtained from Santa Cruz Biotechnology, Inc.
RT-PCR Analysis.
In vitrocultured B cells were sorted and subjected to RT-PCR as described previously (44). PCR products were separated on agarose gels and visualized by ethidium bromide staining. Primer sequences are available upon request.
| Results |
|---|
|
|
|---|
|
Analysis of lymphoid organs revealed that the vast majority of cells expressed no GFP, whereas a minority expressed detectable but low levels (Fig. 1 D). In contrast, high level Blimpgfp expression was restricted to a rare fraction of cells in lymphoid tissues (from 0.1 to 0.5%), many of which also expressed Synd-1, a commonly used marker of ASCs. High level GFP fluorescence was absent from wild-type or lymphoid-deficient Rag2/Blimpgfp/+ cells (Fig. 1 D). Blimpgfp/gfp reconstituted animals lacked a distinct GFPhi compartment and Synd-1 expression (unpublished data). Consistent with a previously published paper (10), Blimpgfp/gfp reconstituted mice had severely reduced numbers of BM and splenic plasma cells as measured by ELISPOT (unpublished data).
All Blimpgfp High Cells Are ASCs.
To determine the concordance between high Blimpgfp expression in the heterozygous reporter mice and ASC function, we performed Ig ELISPOT assays on sorted cell populations from spleen and BM using GFP as the only sorting parameter. These experiments showed that Blimpgfp-expressing cells represented a pure population of ASCs, as the GFP+ fraction contained a high proportion of Ig-secreting cells, whereas 105 GFP cells lacked ASC activity (Fig. 2 A). The GFP+ population contained all Ig isotypes at the expected ratios and, furthermore, the proportion of ASCs was similarly high in both the Synd-1+GFP+ and Synd-1GFP+ fraction (Fig. 2 A). Therefore, the Blimpgfp reporter allele allows the single parameter identification of all ASC, with an enrichment of
105-fold over nonexpressing cells.
|
The ability to identify distinct populations of ASCs based on Blimp-1 expression levels enabled us to examine their cell surface phenotype. Synd-1 expression is commonly used to identify mouse ASCs, although there are reports of Synd-1 ASCs (22). Analysis of Blimpgfp-expressing cells revealed the existence of Synd-1+ and Synd-1 ASC, with the majority of Synd-1 cells being GFPhi (Figs. 1 D and 2 C). RT-PCR analysis confirmed that the loss of Synd-1 expression occurred at the transcriptional level and was not the result of shedding (Fig. 2 E). GFP+ cells were also heterogeneous for other reported ASC markers examined, including CD43, CD62L, and CD38 (Fig. 2 C). In contrast, the chemokine receptors CXCR5 and CXCR4 were modulated as expected for an ASC population (Fig. 2 C). Thus, plasma cells are a heterogeneous population defined by increasing Blimp-1 expression.
Induction of Blimp-1 Expression by Polyclonal and Antigen-specific Stimuli.
Antibody secretion and Blimp-1 expression are induced by antigen-specific and polyclonal stimuli (35, 8). We have used LPS to examine the kinetics and phenotype of ASCs induced in vivo. LPS injection increased the numbers of GFP-expressing cells in the spleen from the resting levels of 0.6 ± 0.2% to a peak of 4.7 ± 1.9% after 3 d (Fig. 3 A). Induced cells subsequently appeared in the BM at day 4 and were ASCs as determined by ELISPOT assay (Fig. 3 B and not depicted). The numbers of GFP+ ASCs in both locations rapidly declined, returning to resting values by day 7. Analysis of the surface phenotype of the splenic ASCs suggested that induced Blimpgfp expression occurred in GFPintB220+Synd-1+ cells that subsequently lost B220 and acquired a heterogeneous phenotype for Synd-1 (Fig. 3 A). A very similar profile was observed in the BM. As expected, a similar time course with Blimpgfp/gfp mice revealed no induction of GFP+ cells or increase in serum IgM (unpublished data).
|
|
|
and the secreted form of IgH (µS) as compared with GFP cells from the same cultures. In contrast, although Blimptrunc expression was observed in deficient cells, they failed to up-regulate either Ig chain (Fig. 6 B).
|
Heterogeneity of ASCs In Vitro.
Having observed the heterogeneity of plasma cells in vivo, we were interested to see if this diversity also occurred in vitro. Examination of the LPS-stimulated in vitro differentiation of Blimpgfp/+ B cells revealed this was indeed the case, as only
50% of the GFP+ cells were Synd-1+. In contrast, most (>85%) GFP+ cells were Synd-1+ in CD40L/IL-4/IL-5 stimulated cultures, demonstrating that this ASC heterogeneity can be modified by extrinsic signals (Fig. 7 A).
|
The phenotypic diversity in the sorted fractions was further assayed by RT-PCR. Both GFP+ populations displayed the hallmarks of ASC differentiation (decreased Pax5, AID, CIITA and increased XBP-1, IRF-4, and J-chain); however, the GFP+Synd-1 cells appeared less differentiated, with residual Bcl6, Pax5, AID, and CIITA expression, as well as reduced IgM secretion (Fig. 7, E and G). This conclusion was supported by cell sorting experiments that indicated that, whereas GFP+Synd-1+ cells were fully differentiated and retained their phenotype after reculture, GFP+Synd-1 cells were capable of self-renewal and differentiation into the GFP+Synd-1+ compartment (Fig. 7 F). Finally, a small number of transcripts including Synd-1, bcl2, bcl6, and most clearly CXCR2 were differentially expressed between fractions 2 and 3, further highlighting the heterogeneity of the ASC phenotype (Fig. 7 G).
| Discussion |
|---|
|
|
|---|
A significant finding to come from the analysis of the Blimpgfp-expressing ASCs is the heterogeneity of their generation, phenotype and function. There have been papers documenting heterogeneity in plasma cell phenotypes in mice (22) and humans (24, 25) although in the absence of a clear marker for ASCs, these studies are difficult to interpret. Several antigen combinations are commonly used as indicators of ASCs, including Synd-1, CD62L, CD43, CD38, and loss of B220 and CD19. Our analysis of ASCs from resting, immunized, and LPS-injected mice showed that, whereas all of these markers were altered, no combination identified all ASCs. For example, GFP+ cells expressing a broad range of B220 and Synd-1 can be found in the BM and spleen. Moreover, the time course experiments after LPS injection showed clearly that recently induced ASCs have a distinct (B220+Synd-1int-high) phenotype that precedes the B220 Synd-1 positive or negative state.
The heterogeneity was also apparent in the level of Blimpgfp expression, with approximately equal numbers of GFPint and GFPhi ASCs in the spleen and a predominance of GFPhi cells in the BM (Fig. 2 B). We suggest that the GFPint cells represent the more immature plasma cells that will undergo further differentiation to GFPhi phenotype. This model was supported by the pronounced induction of GFPint cells by LPS injection or immunization (Figs. 3 and 4). These cells had not completely lost CD19 or B220 expression, were short lived, and secreted antibody, whereas GFPhi cells that had more completely down-regulated these markers were quiescent while also secreting Ig. We propose that these GFPint cells represent the plasmablast stage of differentiation, a minority of which increase Blimp-1 expression and enter the long-lived ASC compartment. It is also of note that, whereas blood ASCs are GFPint, the BM ASCs are uniformly GFPhi, suggesting that the increased Blimp-1 expression associated with long-lived BM ASCs occurs after entry to the BM. Interestingly, the in vitrogenerated ASCs continue to proliferate and have a similar fluorescence to the GFPint stage in vivo, suggesting that these cells represent the plasmablast stage. Nothing is known about the regulation of Blimp-1 expression levels in ASCs, but it is an intriguing prospect that stromal cell or antigen affinity determinants regulate entry into the long-lived plasma cell state via increasing Blimp-1 expression.
The ability to differentiate B cells in vitro has enabled us to examine the extrinsic regulation of ASC heterogeneity. Perhaps most striking is the appearance of distinct Blimpgfp-expressing populations after LPS stimulation that can be discerned based on the expression of Synd-1. GFP+Synd-1 cells occur at a similar frequency to GFP+Synd-1+ ASCs but produce significantly less total Ig. The transcriptional profiles of the two populations were similar, with GFP+Synd-1+ cells displaying a trend toward greater divergence from the GFP cells, including the down-regulation of Pax5 and Bcl6, whereas the majority of chemokine receptors were cocoordinately regulated; CXCR2 was specifically expressed in the GFP+Synd-1+ cells. CXCR2 is the receptor for IL-8 and is not known to play a role in ASC biology. We have performed chemotaxis assays with recombinant IL-8, but, to date, have not been able to show any specific migration toward this stimulus by GFP+Synd-1+ ASCs (unpublished data). A recent microarray paper has concluded that Blimp-1 activates distinct genetic programs in two B cell lines depending on the mode of stimulation (20). A more extensive analysis of the transcriptional profiles of the populations identified here will further test this possibility.
ASC heterogeneity also depended on the type of stimuli received, as the equal numbers of GFP+Synd-1+ and GFP+Synd-1 cells produced in LPS cultures contrasted with the preponderance of GFP+Synd-1+ ASCs after CD40L and cytokine-driven differentiation. Previous in vivo studies have suggested that Synd-1 ASCs exist and are derived from Synd-1+ precursors (22). Our results showed that this was not the case in vitro, as sorted GFP+Synd-1+ cells maintained their expression profile for several days after sorting, whereas GFP+Synd-1 cells were capable of self-renewal as well as differentiation into Synd-1+ cells. We suggest that there are two distinct pathways to GFP+Synd-1+ cells, one that proceeds through the GFP+ Synd-1 intermediate and a second that is derived directly from the GFP population. The existence of these two pathways was supported by the coincidence of their appearance during the time course of LPS induction (unpublished data). Whether Synd-1+ cells give rise to negative cells in vivo is still to be determined, but the LPS injection experiments are compatible with this scenario.
Molecular Role of Blimp-1.
A hallmark of plasma cell differentiation is the silencing of many of the genes associated with the mature B cell phenotype, whereas Blimp-1 is activated by stimuli that induce an ASC fate (4). Blimp-1 functions primarily as a transcriptional repressor (11, 16, 21) that can recruit key players in gene silencing (1214). However, cDNA microarray analysis also identified a cohort of transcripts that are induced by Blimp-1 expression (20, 21). Direct promoter analyses have suggested that Blimp-1 represses Pax5 (17), c-myc (16), and CIITA (36). This paper is the first to use the combination of a reporter of Blimp-1 expression and Blimp-1deficient cells to genetically determine the requirement for Blimp-1 in the regulation of a particular transcript.
A model of B cell terminal differentiation holds that mature B cells express the B cell maintenance factor Pax5 and the oncogene Bcl6. Extrinsic signals such as cytokines or antigen result in the degradation of Bcl6, a repressor of Blimp-1. Blimp-1 activates differentiation to ASCs (30). Interestingly, Pax5 was expressed in all GFP populations, but was rapidly silenced in GFP+ cells, supporting the notion that Pax5 is repressed by Blimp-1 (17) and suggesting that this repression may be the pivotal transcriptional event in ASC differentiation. Indeed, as predicted by this model, the Pax5-repressed genes XBP-1 (18) and J-chain (31) were silent and the Pax5-activated genes AID (32) and CIITA (33) were maintained in Blimp-1deficient cells (Fig. 6 C).
Using several experimental systems, we and others have demonstrated that very low levels of Ig were produced by Blimp-1deficient plasma cells (10). As Blimp-1 is not implicated directly in Ig transcription, it is likely that its role in inducing Ig production occurs via secondary proteins such as Pax5, IRF4, and XBP-1. Pax5 regulates Ig production by repressing IgH and Ig
expression (for review see reference 37), whereas IRF4 binds in the Ig
3' and
2-4 enhancers and is essential for Ig production (3840). As Blimp-1deficient B cells maintain Pax5 and lack IRF4, the inability to activate appropriate Ig transcription levels would limit the secretion rate and explain the inability of XBP-1 alone to rescue Ig secretion by Blimp-1/ B cells as XBP-1 functions after high level Ig production has been initiated (10, 41). Together, these data suggest that the inability of Blimpgfp/gfp cells to repress Pax5 and activate IRF4 is sufficient to explain the decreased Ig expression associated with the phenotype.
Blimp-1 Expression Levels Control the Plasma Cell Terminal Differentiation Pathway.
The Blimpgfp allele described here allows the identification and characterization of all ASCs. Our data suggest that Blimp-1 expression is induced in distinct phases; an intermediate expression level associated with short-lived plasmablasts and a more differentiated, long-lived, Blimp-1high phenotype. Although a broad heterogeneity of the plasma cell lineage is apparent at the level of cell surface phenotype, Ig secretion, and transcriptional profiles, these are significantly correlated with expression levels of Blimp-1. These data suggest a model of cellular ontogeny where increasing Blimp-1 levels result in progressive maturation of ASCs (Fig. 8). Short-lived plasmablasts in the spleen in vivo and in vitro, characterized by low Blimp-1 levels, which have not completely extinguished the mature B cell expression profile, proliferate and secrete Ig. In contrast, long-lived, noncycling plasma cells in the spleen and BM are associated with higher Blimp-1 levels and have more completely down-regulated expression of B lineage proteins and genes, but retain some heterogeneity for known plasma cell markers. Although it is not yet possible to ascertain if a linear relationship between Blimp-1 levels and cellular differentiation exists, the Blimpgfp model provides us with the a valuable tool to resolve this question.
|
| Acknowledgments |
|---|
This research was supported by The Walter and Eliza Hall Institute Metcalf Fellowship (S. Nutt), the Deutsche Forschungsgemeinschaft (A. Kallies), and the National Health and Medical Research Council of Australia.
The authors have no conflicting financial interests.
Submitted: 17 May 2004
Accepted: 24 August 2004
| References |
|---|
|
|
|---|
1 Manz, R.A., S. Arce, G. Cassese, A.E. Hauser, F. Hiepe, and A. Radbruch. 2002. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol. 14:517521.[CrossRef][Medline]
2 Manz, R.A., M. Lohning, G. Cassese, A. Thiel, and A. Radbruch. 1998. Survival of long-lived plasma cells is independent of antigen. Int. Immunol. 10:17031711.
3 Angelin-Duclos, C., G. Cattoretti, K.I. Lin, and K. Calame. 2000. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 165:54625471.
4 Turner, C.A., Jr., D.H. Mack, and M.M. Davis. 1994. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 77:297306.[CrossRef][Medline]
5 Schliephake, D.E., and A. Schimpl. 1996. Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-mu F(ab')2-co-stimulated B lymphocytes. Eur. J. Immunol. 26:268271.[Medline]
6 Messika, E.J., P.S. Lu, Y.J. Sung, T. Yao, J.T. Chi, Y.H. Chien, and M.M. Davis. 1998. Differential effect of B lymphocyteinduced maturation protein (Blimp-1) expression on cell fate during B cell development. J. Exp. Med. 188:515525.
7 Knodel, M., A.W. Kuss, I. Berberich, and A. Schimpl. 2001. Blimp-1 over-expression abrogates IL-4- and CD40-mediated suppression of terminal B cell differentiation but arrests isotype switching. Eur. J. Immunol. 31:19721980.[CrossRef][Medline]
8 Soro, P.G., A.P. Morales, M.J. Martinez, A.S. Morales, S.G. Copin, M.A. Marcos, and M.L. Gaspar. 1999. Differential involvement of the transcription factor Blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells. J. Immunol. 163:611617.
9 Angelin-Duclos, C., K. Johnson, J. Liao, K.I. Lin, and K. Calame. 2002. An interfering form of Blimp-1 increases IgM secreting plasma cells and blocks maturation of peripheral B cells. Eur. J. Immunol. 32:37653775.[CrossRef][Medline]
10 Shapiro-Shelef, M., K.I. Lin, L.J. McHeyzer-Williams, J. Liao, M.G. McHeyzer-Williams, and K. Calame. 2003. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 19:607620.[CrossRef][Medline]
11 Keller, A.D., and T. Maniatis. 1991. Identification and characterization of a novel repressor of beta-interferon gene expression. Genes Dev. 5:868879.
12 Ren, B., K.J. Chee, T.H. Kim, and T. Maniatis. 1999. PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev. 13:125137.
13 Yu, J., C. Angelin-Duclos, J. Greenwood, J. Liao, and K. Calame. 2000. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol. Cell. Biol. 20:25922603.
14 Gyory, I., J. Wu, G. Fejer, E. Seto, and K.L. Wright. 2004. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat. Immunol. 5:299308.[CrossRef][Medline]
15 Kakkis, E., K.J. Riggs, W. Gillespie, and K. Calame. 1989. A transcriptional repressor of c-myc. Nature. 339:718721.[CrossRef][Medline]
16 Lin, Y., K. Wong, and K. Calame. 1997. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 276:596599.
17 Lin, K.I., C. Angelin-Duclos, T.C. Kuo, and K. Calame. 2002. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol. Cell. Biol. 22:47714780.
18 Reimold, A.M., P.D. Ponath, Y.S. Li, R.R. Hardy, C.S. David, J.L. Strominger, and L.H. Glimcher. 1996. Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J. Exp. Med. 183:393401.
19 Reimold, A.M., N.N. Iwakoshi, J. Manis, P. Vallabhajosyula, E. Szomolanyi-Tsuda, E.M. Gravallese, D. Friend, M.J. Grusby, F. Alt, and L.H. Glimcher. 2001. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 412:300307.[CrossRef][Medline]
20 Sciammas, R., and M.M. Davis. 2004. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. J. Immunol. 172:54275440.
21 Shaffer, A.L., K.I. Lin, T.C. Kuo, X. Yu, E.M. Hurt, A. Rosenwald, J.M. Giltnane, L. Yang, H. Zhao, K. Calame, and L.M. Staudt. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 17:5162.[CrossRef][Medline]
22 Underhill, G.H., K.P. Kolli, and G.S. Kansas. 2003. Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation. Blood. 102:40764083.
23 O'Connor, B.P., M. Cascalho, and R.J. Noelle. 2002. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J. Exp. Med. 195:737745.
24 Medina, F., C. Segundo, A. Campos-Caro, I. Gonzalez-Garcia, and J.A. Brieva. 2002. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood. 99:21542161.[Medline]
25 Ellyard, J.I., D.T. Avery, T.G. Phan, N.J. Hare, P.D. Hodgkin, and S.G. Tangye. 2003. Ag-selected Ig-secreting cells persist in human spleen as well as bone marrow. Blood. 103:38053812.[Medline]
26 Smith, K.G., A. Light, G.J. Nossal, and D.M. Tarlinton. 1997. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J. 16:29963006.[CrossRef][Medline]
27 Smith, K.G., T.D. Hewitson, G.J. Nossal, and D.M. Tarlinton. 1996. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 26:444448.[Medline]
28 Jacob, J., and G. Kelsoe. 1992. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J. Exp. Med. 176:679687.
29 Hasbold, J., L.M. Corcoran, D.M. Tarlinton, S.G. Tangye, and P.D. Hodgkin. 2004. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat. Immunol. 5:5563.[CrossRef][Medline]
30 Calame, K.L., K.I. Lin, and C. Tunyaplin. 2003. Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 21:205230.[CrossRef][Medline]
31 Rinkenberger, J.L., J.J. Wallin, K.W. Johnson, and M.E. Koshland. 1996. An interleukin-2 signal relieves BSAP (Pax5)-mediated repression of the immunoglobulin J chain gene. Immunity. 5:377386.[CrossRef][Medline]
32 Gonda, H., M. Sugai, Y. Nambu, T. Katakai, Y. Agata, K.J. Mori, Y. Yokota, and A. Shimizu. 2003. The balance between Pax5 and Id2 activities is the key to AID gene expression. J. Exp. Med. 198:14271437.
33 Horcher, M., A. Souabni, and M. Busslinger. 2001. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity. 14:779790.[CrossRef][Medline]
34 Hargreaves, D.C., P.L. Hyman, T.T. Lu, V.N. Ngo, A. Bidgol, G. Suzuki, Y.R. Zou, D.R. Littman, and J.G. Cyster. 2001. A coordinated change in chemokine responsiveness guides plasma cell movements. J. Exp. Med. 194:4556.
35 Lin, K.I., Y. Lin, and K. Calame. 2000. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol. Cell. Biol. 20:86848695.
36 Piskurich, J.F., K.I. Lin, Y. Lin, Y. Wang, J.P. Ting, and K. Calame. 2000. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol. 1:526532.[CrossRef][Medline]
37 Busslinger, M., and S.L. Nutt. 1998. Role of the transcription factor BSAP (Pax-5) in B-cell development. Molecular Biology of B-Cell and T-Cell Development. J.G. Monroe and E.V. Rothenberg, editors. Humana Press, Totowa. 83110.
38 Eisenbeis, C.F., H. Singh, and U. Storb. 1993. PU.1 is a component of a multiprotein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer. Mol. Cell. Biol. 13:64526461.
39 Pongubala, J.M., S. Nagulapalli, M.J. Klemsz, S.R. McKercher, R.A. Maki, and M.L. Atchison. 1992. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3' enhancer activity. Mol. Cell. Biol. 12:368378.
40 Mittrucker, H.W., T. Matsuyama, A. Grossman, T.M. Kundig, J. Potter, A. Shahinian, A. Wakeham, B. Patterson, P.S. Ohashi, and T.W. Mak. 1997. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 275:540543.
41 Iwakoshi, N.N., A.H. Lee, P. Vallabhajosyula, K.L. Otipoby, K. Rajewsky, and L.H. Glimcher. 2003. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4:321329.[CrossRef][Medline]
42 Kehry, M.R., and B.E. Castle. 1994. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin. Immunol. 6:287294.[CrossRef][Medline]
43 Rosenbauer, F., A. Kallies, M. Scheller, K.P. Knobeloch, C.O. Rock, M. Schwieger, C. Stocking, and I. Horak. 2002. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J. 21:211220.[CrossRef][Medline]
44 Nutt, S.L., S. Vambrie, P. Steinlein, Z. Kozmik, A. Rolink, A. Weith, and M. Busslinger. 1999. Independent regulation of the two Pax5 alleles during B-cell development. Nat. Genet. 21:390395.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|